Migraine preventive therapy has followed a predictable order for years: oral agents first, CGRP-targeted therapies reserved for treatment failures. Dr. O'Brien reviews the evidence testing that hierarchy — where CGRP monoclonal antibodies and gepants now fit as first-line options, who qualifies, and how updated society guidance is reshaping prescribing decisions for clinicians managing migraine in primary care and ob-gyn settings.

Hope O’Brien, MD, MBA, FAHS, FAAN, is the founder and CEO of Headache Center of Hope.  Dr. O’Brien was born on Long Island, New York, to parents, both of whom are registered nurses and of Jamaican descent.  

Dr. O’Brien is an award-winning neurologist who brings years of experience to her practice along with extensive education in Neuroscience and training in Clinical Neurology & Headache Medicine. She completed her residency in adult neurology at the University of Cincinnati. Dr. O’Brien went on to study headache medicine and was recruited to join the faculty at Cincinnati Children's Hospital Medical Center. While there, she established the Young Adult Headache Program, which focused on the needs of adolescents and young adults (ages 15-26) with headaches. 

Dr. O’Brien’s research endeavors have centered on the improvement of outcomes for patients with migraines and have resulted in numerous publications and lecture presentations.  Her vision is to see patients, regardless of age, return to the life they love.